PAMU
CCCC icon

Pictet Asset Management (UK)’s C4 Therapeutics CCCC Stock Holding History

Pictet Asset Management (UK)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$30.7M Buy
810,634
+326,867
+68% +$11.7M 0.03% 439
2021
Q1 		$17.9M Buy
483,767
+319,996
+195% +$12.7M 0.02% 525
2020
Q4 		$5.43M Buy
+163,771
New +$4.75M 0.01% 800

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management (UK)'s CCCC Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its C4 Therapeutics (CCCC) stake by 68% in Q2 2021, buying an estimated $11.7M and bringing the position to 810,634 shares worth $30.7M. The position accounts for 0.03% of the portfolio, ranked #439.

Pictet Asset Management (UK) first reported a position in CCCC in Q4 2020 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold CCCC as of Q2 2021.

  • Pictet Asset Management (UK) held 810,634 shares of C4 Therapeutics worth $30.7M as of Q2 2021.
  • Pictet Asset Management (UK) bought 326,867 C4 Therapeutics shares in Q2 2021, an estimated $11.7M.
  • C4 Therapeutics made up 0.03% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #439 holding.
  • Pictet Asset Management (UK) first reported a position in C4 Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 107 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.